Expression of the Adenovirus Early Gene 1A Transcription-Repression Domain Alone Downregulates HER2 and Results in the Death of Human Breast Cancer Cells Upregulated for the HER2 Proto-Oncogene

Genes and Cancer

Volumn 2, Issue 7, 2011, Pages 737-744

  Loewenstein, Paul M ^a   Green, Maurice ^a,b  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Doisy Research Center   (United States)

Author keywords

adenovirus; E1A; HER2; oncogene addiction; transcription repression

Indexed keywords

EARLY GENE IA PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GENE THERAPY AGENT; UNCLASSIFIED DRUG;

ADENOVIRUS; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CANCER GENE THERAPY; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; HER2 GENE; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTO ONCOGENE; TRANSCRIPTION REGULATION; TRANSCRIPTION TERMINATION;

EID: 84857379940     PISSN: 19476019     EISSN: 19476027     Source Type: Journal    
DOI: 10.1177/1947601911426570     Document Type: Article

References (35)

1. Moasser MM.The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis.Oncogene. 2007;26:6469-87.
2. Moasser MM.Targeting the function of the HER2 oncogene in human cancer therapeutics.Oncogene. 2007;26:6577-92.
3. Choudhury A,Charo J,Parapuram SK, et al.Small interfering RNA (siRNA) inhibits the expression of the Her2/Neu gene, upregulates HLA class I and induces apoptosis of Her2Neu positive tumor cell lines.Int J Cancer. 2003;108:71-7.
4. Weinstein IB.Cancer. Addiction to oncogenes-the Achilles heal of cancer.Science. 2002;297:63-4.
5. Weinstein IB,Joe A.Oncogene addiction.Cancer Res. 2008;68:3077-80.
6. Felsher DW,Bishop JM.Transient excess of MYC activity can elicit genomic instability and tumorigenesis.Proc Natl Acad Sci USA. 1999;96:3940-4.
7. Jain M,Arvanitis C,Chu K, et al.Sustained loss of a neoplastic phenotype by brief inactivation of MYC.Science. 2002;297:102-4.
8. Pelengaris S,Littlewood T,Khan M, et al.Reversible activation of c-Myc in skin: induction of a complex neoplastic phenotype by a single oncogenic lesion.Mol Cell. 1999;3:565-77.
9. Chin L,Tam A,Pomerantz J, et al.Essential role for oncogenic Ras in tumour maintenance.Nature. 1999;400:468-72.
10. Huettner CS,Zhang P,Van Etten RA, et al.Reversibility of acute B-cell leukaemia induced by BCR-ABL1.Nat Genet. 2000;24:57-60.
11. Beuzeboc P,Scholl S,Garau XS, et al.Herceptin, a monoclonal humanized antibody anti-HER2: a major therapeutic progress in breast cancers overexpressing this oncogene?.Bull Cancer. 1999;86:544-9.
12. Lillie JW,Loewenstein PM,Green MR, et al.Functional domains of adenovirus type 5 E1a proteins.Cell. 1987;50:1091-100.
13. Green M,Loewenstein PM,Pusztai R, et al.An adenovirus E1A protein domain activates transcription in vivo and in vitro in the absence of protein synthesis.Cell. 1988;53:921-6.
14. Yan DH,Chang LS,Hung MC.Repressed expression of the HER2/c-erbB-2 proto-oncogene by the E1a gene products.Oncogene. 1991;2:343-5.
15. Yu D,Suen T,Yan D, et al.Transcriptional repression of the neu protooncogene by the adenovirus 5 E1A gene products.Proc Natl Acad Sci USA. 1990;87:4499-503.
16. Yu DH,Scorsone K,Hung MC, et al.Adenovirus type 5 E1A gene products act as transformation suppressors of the neu oncogene.Mol Cell Biol. 1991;3:1745-50.
17. Song CZ,Loewenstein PM,Green M.Repression in vitro, by human adenovirus E1A protein domains, of basal or Tat-activated transcription of the human immunodeficiency virus type 1 long terminal repeat.J Virol. 1995;69:2907-11.
18. Song CZ,Tierney CJ,Loewenstein PM, et al.Transcriptional repression by human adenovirus E1A N terminus/conserved domain 1 polypeptides in vivo and in vitro in the absence of protein synthesis.J Biol Chem. 1995;270:23263-7.
19. Song CZ,Loewenstein PM,Toth K, et al.Transcription factor TFIID is a direct functional target of the adenovirus E1A transcription-repression domain.Proc Natl Acad USA. 1995;92:10330-3.
20. Song CZ,Loewenstein PM,Toth K, et al.The adenovirus E1A repression domain disrupts the interaction between the TATA binding protein and the TATA box in a manner reversible by TFIIB.Mol Cell Biol. 1997;17:2186-93.
21. Boyd JM,Loewenstein PM,Tang Q, et al.Adenovirus E1A N-terminal amino acid sequence requirements for repression of transcription in vitro and in vivo correlate with those required for E1A interference with TBP-TATA complex formation.J Virol. 2002;76:1461-74.
22. Loewenstein PM,Arackal S,Green M.Mutational and functional analysis of an essential subdomain of the adenovirus E1A N-terminal transcription repression domain.Virology. 2006;351:312-21.
23. Green M,Panesar NK,Loewenstein PM.Adenovirus E1A proteins are closely associated with chromatin in productively infected and transformed cells.Virology. 2008;371:1-7.
24. Green M,Panesar NK,Loewenstein PM.The transcription-repression domain of the adenovirus E1A oncoprotein targets p300 at the promoter.Oncogene. 2008;27:4446-55.
25. Soule HD,Maloney TM,Wolman, et al.Isolation and characterization of a spontaneously immortalized human epithelial cell line, MCF-10.Cancer Res. 1990;50:6075-86.
26. Clarke R, Leonessa F, Brunner N, et al. In vitro models of breast cancer. In: Harris, JR, Lippman ME, Morrow M, Osborne, CK, editors. Diseases of the breast. 2nd ed. Philadelphia: Lippincott Williams & Wilkins; 2000. p. 335-54.
27. Ueno NT,Dihua Y,Hung MC.Chemosensitization of HER2/neu-overexpressing human breast cancer cells to paclitaxel (Taxol) by adenovirus type 5 E1A.Oncogene. 1997;15:953-60.
28. Fan WH,Lu YL,Deng F, et al.EGFR antisense RNA blocks expression of the epidermal growth factor receptor and partially reverse the malignant phenotype of human MDA-MB-231 cells.Cell Research. 1998:63-71.
29. Luo J,Solimini NL,Elledge SJ.Principles of cancer therapy: Oncogene and non-oncogene addiction.Cell. 2009;136:823-36.
30. Seidman AD,Fornier MN,Esteva FJ, et al.Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification.J Clin Oncol. 2001;19:2587-95.
31. Miller KD.The role of ErbB inhibitors in trastuzumab resistance.Oncologist. 2004;9 (suppl 3): 16-9.
32. Korkaya H,Paulson A,Iovino F, et al.HER2 regulates the mammary stem/progenitor cell population driving tumorigenesis and invasion.Oncogene. 2008;27:6120-30.
33. Yu L,Kamo S,Tagawa M.Identification of a minimal c-ergB-2 promoter region that mediates preferential expression of a linked foreign gene in human breast cancer cells.Int J Oncol. 2002;20:607-10.
34. Howe JA,Mymryk JS,Egan C, et al.Retinoblastoma growth suppressor and a 300-kDa protein appear to regulate DNA synthesis.Proc Natl Acad Sci USA. 1990;87:5883-7.
35. Green M,Loewenstein PM.Human adenoviruses: propagation, purification, quantification, and storage.Curr Protocols in Microbiology. 2005;:14C.1-14C.19.